uniQure (QURE) Operating Expenses (2016 - 2026)
uniQure (QURE) posted quarterly Operating Expenses of $51.7 million for Q2 2026, up 4.32% year-over-year from $49.5 million in Q2 2025, and up 4.48% quarter-over-quarter from $49.5 million in Q1 2026.
Analysis
uniQure (QURE) Operating Expenses (2016 - 2026) Analysis & Trends
uniQure's Operating Expenses history runs 11 years deep, the most recent figure standing at $51.7 million for Q2 2026.
- In Q2 2026, Operating Expenses rose 4.32% year-over-year to $51.7 million; the TTM figure through Jun 2026 stood at $212.2 million (up 11.2% YoY), while the FY2025 annual figure was $207.8 million, down 3.24% from the prior year.
- Operating Expenses for Q2 2026 stood at $51.7 million, up from $49.5 million in the prior quarter.
- The five-year high for Operating Expenses was $84.5 million in Q3 2023, with the low at $43.2 million in Q3 2024.
- The 5-year median for Operating Expenses is $56.9 million (2024), against an average of $60.2 million.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses jumped 44.83% in 2023, then slumped 48.87% in 2024.
- uniQure's Operating Expenses stood at $78.2 million in 2022, then declined by 11.88% to $68.9 million in 2023, then slipped by 26.26% to $50.8 million in 2024, then climbed by 11.79% to $56.8 million in 2025, then retreated by 9.06% to $51.7 million in 2026.
- Business Quant data shows QURE's Operating Expenses at $51.7 million in Q2 2026, $49.5 million in Q1 2026, and $56.8 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.05 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 960.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 505.13 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.21 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 541.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 427.03 Mn |
| 10 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 51.68 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 51.68 Mn |
| Mar 31, 2026 | 49.46 Mn |
| Dec 31, 2025 | 56.83 Mn |
| Sep 30, 2025 | 54.20 Mn |
| Jun 30, 2025 | 49.54 Mn |
| Mar 31, 2025 | 47.25 Mn |
| Dec 31, 2024 | 50.84 Mn |
| Sep 30, 2024 | 43.19 Mn |
| Jun 30, 2024 | 56.88 Mn |
| Mar 31, 2024 | 63.86 Mn |
| Dec 31, 2023 | 68.94 Mn |
| Sep 30, 2023 | 84.48 Mn |
| Jun 30, 2023 | 68.57 Mn |
| Mar 31, 2023 | 81.09 Mn |
| Dec 31, 2022 | 78.24 Mn |
| Sep 30, 2022 | 62.25 Mn |
| Jun 30, 2022 | 59.52 Mn |
| Mar 31, 2022 | 55.99 Mn |
| Dec 31, 2021 | 58.10 Mn |
| Sep 30, 2021 | 48.46 Mn |